AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33872045 — intervention group
Group type: EXPERIMENTAL
Intervention: Admission avoidance hospital at home (HAH) with comprehensive geriatric assessment (CGA)
Number of subjects: 1055
Study 33872045 — intervention group
Group type: COMPARATOR
Intervention: Hospital admission with CGA
Number of subjects: 1055
Study 33872045 — intervention group
Group type: EXPERIMENTAL
Intervention: Admission avoidance hospital at home (HAH) with CGA
Number of subjects: 1055
Study 35717008 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote Ischemic Preconditioning (RIPC) applied in 50% (n = 60) of patients
Number of subjects: 120
Study 35717008 — intervention group
Group type: COMPARATOR
Intervention: Control group (no RIPC)
Number of subjects: 120
Study 32119135 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine infusion (2 mg/kg before anesthesia induction and 2 mg/kg/hr during anesthesia)
Number of subjects: 99
Study 32119135 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine infusion
Number of subjects: 99
Study 32119135 — intervention group
Group type: COMPARATOR
Intervention: Control (0.9% normal saline)
Number of subjects: 99
Study 32049573 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtotal tonsillectomy
Number of subjects: 80
Study 32049573 — intervention group
Group type: COMPARATOR
Intervention: Total tonsillectomy
Number of subjects: 80
Study 36104738 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-month choice architecture intervention (menu labelling, prompts, item positioning, feedback)
Number of subjects: 1331
Study 36104738 — intervention group
Group type: COMPARATOR
Intervention: Usual online ordering (control)
Number of subjects: 1331
Study 33433587 — intervention group
Group type: EXPERIMENTAL
Intervention: Convalescent plasma therapy (CPT)
Number of subjects: 0
Study 33433587 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients with mild disease)
Number of subjects: 0
Study 32769888 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted surgery
Number of subjects: 0
Study 32769888 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgical technique
Number of subjects: 0
Study 35787230 — intervention group
Group type: EXPERIMENTAL
Intervention: Vicodin vignette
Number of subjects: 216
Study 35787230 — intervention group
Group type: EXPERIMENTAL
Intervention: Heroin vignette
Number of subjects: 216
Study 35787230 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine vignette
Number of subjects: 216
Study 35787230 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis vignette
Number of subjects: 216
Study 35787230 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall characterization of substance use
Number of subjects: 216
Study 32197029 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital Communication Technology (DCT) tools (Text/Phone call or Email)
Number of subjects: 14978
Study 32197029 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 14978
Study 33012118 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep intervention
Number of subjects: 597
Study 33012118 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination intervention
Number of subjects: 597
Study 33012118 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 597
Study 35072422 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocrown
Number of subjects: 670
Study 35072422 — intervention group
Group type: COMPARATOR
Intervention: Crown with post and core
Number of subjects: 670
Study 35208580 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep dry needling (DDN) on the masseter muscle
Number of subjects: 36
Study 35208580 — intervention group
Group type: COMPARATOR
Intervention: Simulation of the technique (PN)
Number of subjects: 36
Study 35941410 — intervention group
Group type: EXPERIMENTAL
Intervention: C-LEAR approach training
Number of subjects: 20
Study 33899743 — intervention group
Group type: EXPERIMENTAL
Intervention: ‐40 mm Hg INP treatment
Number of subjects: 72
Study 33899743 — intervention group
Group type: COMPARATOR
Intervention: ‐10 mm Hg INP (sham control)
Number of subjects: 72
Study 33899743 — intervention group
Group type: EXPERIMENTAL
Intervention: ‐40 mm Hg INP treatment (for patients with baseline PWD <200 m)
Number of subjects: 72
Study 33899743 — intervention group
Group type: COMPARATOR
Intervention: ‐10 mm Hg INP (sham control, for patients with baseline PWD <200 m)
Number of subjects: 72
Study 32592427 — intervention group
Group type: EXPERIMENTAL
Intervention: WLR ST deviation
Number of subjects: 165
Study 32592427 — intervention group
Group type: EXPERIMENTAL
Intervention: rST elevation
Number of subjects: 165
Study 35915043 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 0
Study 35915043 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 0
Study 35915043 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib
Number of subjects: 0
Study 35915043 — intervention group
Group type: EXPERIMENTAL
Intervention: Casirivimab‐imdevimab
Number of subjects: 0
Study 35915043 — intervention group
Group type: COMPARATOR
Intervention: Other drugs
Number of subjects: 0
Study 36266601 — intervention group
Group type: EXPERIMENTAL
Intervention: CTT without augmentation
Number of subjects: 63
Study 36266601 — intervention group
Group type: EXPERIMENTAL
Intervention: CTT augmented with Mitomycin-C (MMC)
Number of subjects: 63
Study 36266601 — intervention group
Group type: EXPERIMENTAL
Intervention: CTT augmented with Ologen implant
Number of subjects: 63
Study 94013260 — intervention group
Group type: EXPERIMENTAL
Intervention: Active immunization with inactivated hepatitis A vaccine Epaxal Berna
Number of subjects: 0
Study 94013260 — intervention group
Group type: EXPERIMENTAL
Intervention: Active/passive immunization (combination of active and passive immunization)
Number of subjects: 0
Study 94013260 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive immunization with hepatitis A immunoglobulin preparation Globuman
Number of subjects: 0
Study 94013260 — intervention group
Group type: EXPERIMENTAL
Intervention: Active immunization with inactivated hepatitis A vaccine Epaxal Berna (measured with IMX test)
Number of subjects: 0
Study 94013260 — intervention group
Group type: EXPERIMENTAL
Intervention: Active/passive immunization (measured with IMX test)
Number of subjects: 0
Study 94013260 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive immunization (measured with IMX test)
Number of subjects: 0
Study 35986234 — intervention group
Group type: EXPERIMENTAL
Intervention: butylphthalide group: 0.2 g of butylphthalide capsules three times daily plus routine treatment (aspirin 50-300 mg/d, clopidogrel 75 mg/d, etc.)
Number of subjects: 8000
Study 35986234 — intervention group
Group type: COMPARATOR
Intervention: control group: routine treatment (aspirin 50-300 mg/d, clopidogrel 75 mg/d, etc.)
Number of subjects: 8000
Study 35986234 — intervention group
Group type: EXPERIMENTAL
Intervention: butylphthalide group
Number of subjects: 8000
Study 35986234 — intervention group
Group type: COMPARATOR
Intervention: control group
Number of subjects: 8000
Study 33766761 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-hyperglycemic drugs combined with metformin (specific drugs not detailed)
Number of subjects: 1739
Study 33766761 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment regimen effects on emotional distress
Number of subjects: 1739
Study 33766761 — intervention group
Group type: EXPERIMENTAL
Intervention: Validated measures of emotional distress
Number of subjects: 1739
Study 32343483 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) only for patients
Number of subjects: 510
Study 32343483 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) for patients and caregivers
Number of subjects: 510
Study 32343483 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 510
Study 35674827 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training under hot conditions (HOT, 35 °C)
Number of subjects: 15
Study 35674827 — intervention group
Group type: COMPARATOR
Intervention: Endurance training under cool conditions (CON, 18 °C)
Number of subjects: 15
Study 35674827 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (HOT and CON)
Number of subjects: 15
Study 34365036 — intervention group
Group type: EXPERIMENTAL
Intervention: Postprandial plasma response after meals with varying carbohydrate (CHO) content
Number of subjects: 10
Study 34365036 — intervention group
Group type: EXPERIMENTAL
Intervention: Postprandial plasma BCAA patterns
Number of subjects: 10
Study 34365036 — intervention group
Group type: EXPERIMENTAL
Intervention: Postprandial plasma amino acid concentrations
Number of subjects: 10
Study 34365036 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma citrulline
Number of subjects: 10
Study 34365036 — intervention group
Group type: EXPERIMENTAL
Intervention: Postprandial plasma response
Number of subjects: 10
Study 33181890 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive eslicarbazepine acetate (ESL) 10–30 mg/kg/day; maximum 1200 mg/day
Number of subjects: 514
Study 33181890 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive eslicarbazepine acetate (ESL)
Number of subjects: 514
Study 36054556 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.01% atropine eyedrops
Number of subjects: 153
Study 36054556 — intervention group
Group type: COMPARATOR
Intervention: Placebo eyedrops
Number of subjects: 153
Study 32514678 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodized Circuit Training (CT)
Number of subjects: 61
Study 32514678 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional Strength Training (ST)
Number of subjects: 61
Study 32514678 — intervention group
Group type: COMPARATOR
Intervention: Educational Protocol (EP)
Number of subjects: 61
Study 34986477 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcuminoid extract 250 mg four times a day on postoperative days 1-3
Number of subjects: 98
Study 34986477 — intervention group
Group type: COMPARATOR
Intervention: Control group (no curcuminoids)
Number of subjects: 98
Study 33957648 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractionated CO2 laser treatment
Number of subjects: 40
Study 33957648 — intervention group
Group type: COMPARATOR
Intervention: Sham laser treatment
Number of subjects: 40
Study 33031287 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced recovery after surgery (ERAS)
Number of subjects: 60
Study 33031287 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 60
Study 35895514 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher concentrations (≥ median) of 2-hydroxynaphthalene, 1-hydroxyphenanthrene, summed hydroxyphenanthrenes, total summed metabolites
Number of subjects: 358
Study 35895514 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher concentrations (≥ median) of 1-hydroxynaphthalene
Number of subjects: 358
Study 35895514 — intervention group
Group type: COMPARATOR
Intervention: PAH metabolites
Number of subjects: 358
Study 33577946 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease-specific goals (n = 98 [51%] and n = 92 [54%])
Number of subjects: 190
Study 33577946 — intervention group
Group type: EXPERIMENTAL
Intervention: Function-related goals (n = 90 [48%] and n = 61 [36%])
Number of subjects: 190
Study 33577946 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge goals (n = 1 [1%] and n = 17 [10%])
Number of subjects: 190
Study 33577946 — intervention group
Group type: EXPERIMENTAL
Intervention: Goals aligned with clinician treatment goals
Number of subjects: 190
Study 33577946 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence rates
Number of subjects: 190
Study 36036838 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS
Number of subjects: 600
Study 36036838 — intervention group
Group type: COMPARATOR
Intervention: No-TENS
Number of subjects: 600
Study 33274855 — intervention group
Group type: EXPERIMENTAL
Intervention: Naoxueshu oral liquid 10 ml three times a day for seven consecutive days
Number of subjects: 120
Study 33274855 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard medical management only)
Number of subjects: 120
Study 34626579 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-delivered Lifestyle-integrated Functional Exercise Program
Number of subjects: 309
Study 34626579 — intervention group
Group type: COMPARATOR
Intervention: Individually delivered Lifestyle-integrated Functional Exercise Program
Number of subjects: 309
Study 32197640 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongmai Yangxin pill (TMYX)
Number of subjects: 0
Study 32197640 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35283011 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic Follow-Up (SFU)
Number of subjects: 30
Study 35283011 — intervention group
Group type: COMPARATOR
Intervention: Regular Follow-Up (RFU)
Number of subjects: 30
Study 34496832 — intervention group
Group type: EXPERIMENTAL
Intervention: Total wrist arthrodesis with CMCJ arthrodesis
Number of subjects: 120
Study 34496832 — intervention group
Group type: COMPARATOR
Intervention: Total wrist arthrodesis with CMCJ preservation
Number of subjects: 120
Study 32985080 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention to improve detection and treatment of depression in primary care patients receiving ART
Number of subjects: 2002
Study 34569495 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased extracorporeal blood flow rate (BFR) from 0 to 300 mL/min
Number of subjects: 0
Study 34569495 — intervention group
Group type: EXPERIMENTAL
Intervention: Inversion of inlet and outlet lines connected to the catheters
Number of subjects: 0
Study 34569495 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal BFR
Number of subjects: 0
Study 34569495 — intervention group
Group type: EXPERIMENTAL
Intervention: Inflow pressure and outflow pressure
Number of subjects: 0
Study 32860344 — intervention group
Group type: EXPERIMENTAL
Intervention: BWL + BIAS
Number of subjects: 72
Study 32860344 — intervention group
Group type: COMPARATOR
Intervention: BWL
Number of subjects: 72
Study 36196650 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided block
Number of subjects: 50
Study 36196650 — intervention group
Group type: COMPARATOR
Intervention: Conventional block
Number of subjects: 50
Study 32562337 — intervention group
Group type: EXPERIMENTAL
Intervention: Micro-needling
Number of subjects: 30
Study 32562337 — intervention group
Group type: COMPARATOR
Intervention: Fractional CO2 laser
Number of subjects: 30
Study 32648985 — intervention group
Group type: EXPERIMENTAL
Intervention: Cernitin (4 capsules/day)
Number of subjects: 100
Study 32648985 — intervention group
Group type: COMPARATOR
Intervention: Tadalafil (5 mg/d)
Number of subjects: 100
Study 33127596 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg BID (extended induction for 16 weeks)
Number of subjects: 0
Study 33127596 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg BID (initial induction for 8 weeks)
Number of subjects: 0
Study 34270189 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinforcement of colorectal anastomosis (main group)
Number of subjects: 115
Study 34270189 — intervention group
Group type: COMPARATOR
Intervention: No reinforcement (control group)
Number of subjects: 115
Study 34270189 — intervention group
Group type: EXPERIMENTAL
Intervention: Transabdominal reinforcement (main group)
Number of subjects: 115
Study 34270189 — intervention group
Group type: COMPARATOR
Intervention: No transabdominal reinforcement (control group)
Number of subjects: 115
Study 34270189 — intervention group
Group type: EXPERIMENTAL
Intervention: Transanal reinforcement (main group)
Number of subjects: 115
Study 34270189 — intervention group
Group type: COMPARATOR
Intervention: No transanal reinforcement (control group)
Number of subjects: 115
Study 36221799 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose levodopa/carbidopa eye drops (1.4 levodopa:0.34 carbidopa [μmoles/day], n=14)
Number of subjects: 29
Study 36221799 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard dose levodopa/carbidopa eye drops (2.7 levodopa:0.68 carbidopa [μmoles/day], n=15)
Number of subjects: 29
Study 36221799 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in fellow eye)
Number of subjects: 29
Study 32965047 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 159
Study 32965047 — intervention group
Group type: COMPARATOR
Intervention: Glibenclamide
Number of subjects: 159
Study 35279384 — intervention group
Group type: EXPERIMENTAL
Intervention: SCS + PNFS
Number of subjects: 75
Study 35279384 — intervention group
Group type: COMPARATOR
Intervention: SCS-only
Number of subjects: 75
Study 35868341 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily dolutegravir with rifampicin
Number of subjects: 37
Study 35868341 — intervention group
Group type: COMPARATOR
Intervention: Rifampicin
Number of subjects: 37
Study 35868341 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily dolutegravir
Number of subjects: 37
Study 33053252 — intervention group
Group type: EXPERIMENTAL
Intervention: DC/TMD instructional video
Number of subjects: 50
Study 33053252 — intervention group
Group type: COMPARATOR
Intervention: DC/TMD manual (control group)
Number of subjects: 50
Study 32221587 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose methotrexate 15 mg weekly
Number of subjects: 4168
Study 32221587 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4168
Study 32221587 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline IL-6
Number of subjects: 4168
Study 32221587 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline hsCRP
Number of subjects: 4168
Study 32221587 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline LDLC
Number of subjects: 4168
Study 32221587 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated levels of both cholesterol and inflammation (IL-6 and LDLC)
Number of subjects: 4168
Study 32221587 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated levels of both cholesterol and inflammation (hsCRP and LDLC)
Number of subjects: 4168
Study 35969360 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefapixant 45 mg
Number of subjects: 46
Study 35969360 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 36273162 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy via teleconference (5 weekly sessions)
Number of subjects: 280
Study 36273162 — intervention group
Group type: COMPARATOR
Intervention: Active control group (access to 15 videos covering the same topics)
Number of subjects: 280
Study 33247529 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (Lactobacillus plantarum CJLP243), taken once daily from preoperative day 1 to day 21
Number of subjects: 40
Study 33247529 — intervention group
Group type: COMPARATOR
Intervention: Placebo, taken once daily from preoperative day 1 to day 21
Number of subjects: 40
Study 33247529 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (Lactobacillus plantarum CJLP243)
Number of subjects: 40
Study 33247529 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 35147724 — intervention group
Group type: EXPERIMENTAL
Intervention: L-DOPA
Number of subjects: 65
Study 35147724 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 35077331 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 min warm-up
Number of subjects: 13
Study 35077331 — intervention group
Group type: COMPARATOR
Intervention: 10 min warm-up
Number of subjects: 13
Study 33588379 — intervention group
Group type: EXPERIMENTAL
Intervention: Aqua-cycling session in 18 °C (EXO18)
Number of subjects: 30
Study 33588379 — intervention group
Group type: COMPARATOR
Intervention: Aqua-cycling session in 27 °C (EXO27)
Number of subjects: 30
Study 33588379 — intervention group
Group type: COMPARATOR
Intervention: Aqua-cycling sessions (EXO18 and EXO27)
Number of subjects: 30
Study 36301961 — intervention group
Group type: EXPERIMENTAL
Intervention: B-vitamin/folate therapy (folic acid, vitamins B12, B6)
Number of subjects: 1952
Study 36301961 — intervention group
Group type: EXPERIMENTAL
Intervention: B-vitamin/folate therapy (folic acid, vitamin B12)
Number of subjects: 1952
Study 36301961 — intervention group
Group type: EXPERIMENTAL
Intervention: B-vitamin/folate therapy (vitamin B6)
Number of subjects: 1952
Study 36301961 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1952
Study 36301961 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline CLT (>cutoff)
Number of subjects: 1952
Study 36301961 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline Absmax (>cutoff)
Number of subjects: 1952
Study 36301961 — intervention group
Group type: EXPERIMENTAL
Intervention: Cys and uHcy-thiolactone
Number of subjects: 1952
Study 33630934 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymmetric real-time feedback about step timing
Number of subjects: 29
Study 33630934 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymmetric real-time feedback about step position
Number of subjects: 29
Study 33630934 — intervention group
Group type: COMPARATOR
Intervention: No feedback
Number of subjects: 29
Study 32103064 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Fitness (PF) measured with Chair Stand Test
Number of subjects: 6874
Study 32103064 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) levels (low, moderate, high)
Number of subjects: 6874
Study 32103064 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Fitness (PF) and Physical Activity (PA) levels
Number of subjects: 6874
Study 34454599 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthodontic treatment before alveolar bone grafting
Number of subjects: 0
Study 34454599 — intervention group
Group type: COMPARATOR
Intervention: No orthodontic treatment
Number of subjects: 0
Study 34454599 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthodontic treatment
Number of subjects: 0
Study 32623488 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-surgical hypoPT patients
Number of subjects: 94
Study 35789192 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 0
Study 35789192 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33861211 — intervention group
Group type: EXPERIMENTAL
Intervention: CAREs + community-based rehabilitation
Number of subjects: 40
Study 33861211 — intervention group
Group type: COMPARATOR
Intervention: Community-based rehabilitation only
Number of subjects: 40
Study 36328358 — intervention group
Group type: EXPERIMENTAL
Intervention: GLPG1205 100 mg
Number of subjects: 68
Study 36328358 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68